[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-adult-volunteers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-adult-volunteers":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,68,91,120,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100651752","phase-1-a-phase-1-study-of-fxr0906-in-healthy-adults-with-or-without-elevated-triglycerides-100651752",false,"NCT07766759","A Phase 1 Study of FXR0906 in Healthy Adults With or Without Elevated Triglycerides","A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FXR0906 in Healthy Adult Participants With or Without Elevated Triglycerides","Inclusion criteria：\n\n1\\. Males or females aged ≥18 and ≤55 years at the time of screening; 2. Body mass index (BMI) ≥18.0 and ≤35.0 kg\u002Fm² at the time of screening, with female participants weighing \\>45 kg and male participants weighing \\>50 kg; 3. Fasting serum triglyceride (TG) level TG \\> 80 mg\u002FdL (0.90 mmol\u002FL) during screening; 4. Fasting LDL-C level ≥ 70 mg\u002FdL (1.81 mmol\u002FL) during screening; Exclusion criteria: 1. History or presence of clinically significant diseases\u002Fabnormality, or with clinically significant symptoms\u002Fsigns, or self-reported diseases, unsuitable for enrollement in the judgement of the investigator.\n\n2\\. Fasting blood glucose ≥7.0 mmol\u002FL or HbA1c ≥6.5% during screening. 3. Use of any lipid-lowering treatment (e.g., drugs lowering LDL-C or TG), including but not limited to statins, ezetimibe, fibrates, omega-3 fatty acids, nutritional supplements, or other treatment regimens altering serum lipids within 30 days prior to screening, or use of any ASO or siRNA therapies lowering serum lipids within 12 months prior to screening..\n\n4\\. Use of investigational drugs or instruments within 3 months prior to screening , or plans to participate in other clinical trials during this study. 5. Clinical laboratory parameters during screening meeting any of the following criteria:\n\n1. ALT and\u002For AST \\>1.5 × ULN\n2. ALT and\u002For AST \\> ULN and ≤1.5 × ULN, deemed clinically significant and unsuitable for participation in the clinical trial by the investigator\n3. INR \\> ULN, deemed clinically significant and unsuitable for participation in the clinical trial by the investigator\n4. Estimated glomerular filtration rate (eGFR) \\\u003C90 mL\u002Fmin\u002F1.73 m2 (using MDRD formula)\n5. Other examination abnormalities deemed clinically significant and unsuitable for participation in the clinical trial by the investigator",true,"ALL","18 Years","55 Years",{"count":21,"type":22},24,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics effects of a single dose of FXR0906 injection or placebo in Chinese healthy adult volunteers with or without TG increase.",[28],"Healthy Adult Volunteers","NOT_YET_RECRUITING","2026-08-10",{"date":32,"type":33},"2026-08-14","ACTUAL",{"date":35,"type":22},"2026-08-25",{"date":37,"type":22},"2027-12-20",{"name":39,"class":40},"Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100650842","the-effects-of-the-yi-jin-jing-on-the-muscles-and-bones-of-adults-100650842","NCT07753291","The Effects of the Yi Jin Jing on the Muscles and Bones of Adults","Inclusion Criteria:\n\n* Age 18-90 years inclusive;\n* Generally healthy, no acute or chronic diseases affecting major organ functions;\n* No cognitive impairment, able to understand and comply with study procedures;\n* Willing and able to provide written informed consent;\n* No pregnancy or lactation (for females);\n* No recent (within 3 months) major surgery, hospitalization, or significant weight change (\\>5% body weight).\n\nExclusion Criteria:\n\n* Presence of acute or unstable chronic diseases (e.g., uncontrolled hypertension, diabetes, heart failure, or malignancy);\n* Severe cognitive impairment, psychiatric disorders, or inability to follow study instructions;\n* Recent (≤3 months) major surgery, trauma, or hospitalization;\n* Pregnancy, lactation, or childbearing potential without reliable contraception;\n* Body mass index (BMI) \\\u003C16 or \\>40 kg\u002Fm²;\n* Current use of medications affecting muscle or nutritional metabolism (e.g., corticosteroids, anabolic steroids);\n* Participation in another interventional trial within 30 days.","90 Years",{"count":50,"type":22},50,[52],"NA","Observation of the effects of Yi Jin Jing on the muscles and bones of adults",[55,28],"Musculoskeletal Health",[57,28,55],"Yijinjing","RECRUITING",{"date":60,"type":33},"2026-08-12",{"date":62,"type":22},"2026-07-19",{"date":64,"type":22},"2028-12-31",{"name":66,"class":67},"Beijing Hospital of Traditional Chinese Medicine","OTHER",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":16,"sex":17,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":41},"100646596","phase-1-multiple-ascending-dose-study-of-dw4421-100646596","NCT07691242","Multiple Ascending Dose Study of DW4421","A Phase 1 Clinical Trial to Evaluate the Safety, the Pharmacokinetics and Pharmacodynamics After Multiple Administration of DW4421 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult aged 19 to 50 (inclusive) years, at the time of screening.\n* Subjects weighing between 50 kg and 90 kg with BMI between 18 and 27 kg\u002Fm2 (inclusive) at screening visit.\n\nExclusion Criteria:\n\n* Those who have clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history.","19 Years","50 Years",{"count":78,"type":22},56,[25],"Multiple Ascending Dose of DW4421, phase I",[28],"2026-07-02",{"date":84,"type":33},"2026-07-08",{"date":86,"type":22},"2026-09",{"date":88,"type":22},"2027-02",{"name":90,"class":40},"Daewon Pharmaceutical Co., Ltd.",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":102,"conditions":103,"keywords":107,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":41},"100632588","immun4cure-cohort-of-autoimmune-diseases-100632588","NCT07515638","Immun4Cure Cohort of Autoimmune Diseases","Prospective Cohort Study of Clinical and Biological Data in Patients With Autoimmune Diseases (Immun4Cure Cohort)","Immun4Cure","Inclusion Criteria Participants:\n\nGroup 1: RA\n\n* Adults ≥18 years\n* Patient followed as part of their MAI in one of the departments participating in the study at UHM\n* Confirmed diagnosis according to international criteria :ACR\u002FEULAR 2010\n\nGroup 2: LES\n\n* Adults ≥18 years\n* Patient followed as part of their MAI in one of the departments participating in the study at UHM\n* Confirmed diagnosis according to international criteria :ACR\u002FEULAR 2019\n\nGroup 3: SSc\n\n* Adults ≥18 years\n* Patient followed as part of their MAI in one of the departments participating in the study at UHM\n* Confirmed diagnosis according to international criteria :ACR\u002FEULAR 2013\n\nGroup 4: Healthy Controls\n\n* Adults ≥18 years\n* No symptoms of autoimmune disease\n* No first-degree family history of autoimmune disease\n\nExclusion Criteria (all groupes):\n\n* Patients who have refused or are unable to give informed consent\n* Inability to follow the subject during the study period\n* Participation in another interventional study that includes an exclusion period that is still ongoing\n* Pregnant women\n* Not affiliated with a social security scheme\n* Patients without a national insurance number\n* Persons under judicial protection, guardianship or trusteeship\n* Persons deprived of their liberty",{"count":100,"type":22},500,"OBSERVATIONAL","This prospective cohort study aims to constitute a 500-participant database and biobank including 450 adults with systemic autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis) and 50 healthy controls.",[104,105,106,28],"Rheumatoid Arthritis","Systemic Lupus Erythematosus","Systemic Sclerosis",[108,109,110],"Autoimmune disease","multi-omic profiling","immunology","2026-06-26",{"date":113,"type":33},"2026-06-30",{"date":115,"type":33},"2026-06-23",{"date":117,"type":22},"2034-06-23",{"name":119,"class":67},"University Hospital, Montpellier",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":16,"sex":17,"minAge":128,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":23,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":41},"100637470","effects-of-plant-foods-on-gastrointestinal-and-cardiometabolic-health-100637470","NCT07586111","Effects of Plant Foods on Gastrointestinal and Cardiometabolic Health","A Randomised Controlled Trial Investigating the Impact of Plant Foods on Gastrointestinal and Cardiometabolic Health","PLANTIFUL","Inclusion Criteria:\n\n* Adults aged 30-70 years of age\n* Capacity to give informed consent in English\n* Consume equal or less than the average UK plant food intake (number and quantity)\n* Consume less than 30 g\u002Fd of fibre\n* BMI 18.50-29.99 kg\u002Fm2\n* Willing to complete the trial by adhering to the diet intervention, complete questionnaires, provide stool, urine and blood samples, record weight and other anthropometric values and record food intake throughout the study\n* Willing and able to adhere to the protocol for the diet intervention for the whole duration of the trial (e.g., appropriate space in freezer to store meals, access to oven\u002Fmicrowave, no planned travelling)\n* Willing to discontinue use of prebiotics and probiotics 4 weeks prior and during the intervention period\n* Willing to consume animal products daily\n* Medication use is stable in women receiving hormone replacement therapy (stable use for the past 3 months)\n\nExclusion Criteria:\n\n* Medical history of any of the following: diabetes, major active or historic psychiatric conditions (e.g., schizophrenia), current eating disorder, alcohol abuse, active treatment for cancer in the last year, severe neurological, endocrine, renal, cardiac or pulmonary disease (or any other chronic medical condition), severe oesophagitis, gastritis or duodenitis, active diverticulitis or intestinal\u002Fcolonic strictures, Coeliac disease, Crohn's disease or Ulcerative colitis, stem cell or organ transplant, gut resection surgery (excluding appendicectomy and cholecystectomy), bleeding disorder, anaphylaxis or any other major or chronic condition known to impact study outcome measures.\n* A current diagnosis of IBS, as defined by the Rome IV criteria.\n* Taking medications known to affect outcomes of interest, including:\n* Prebiotics and probiotics 4 weeks prior to enrolment.\n* Antibiotics within 4 weeks of enrolment.\n* Medications known to affect blood pressure, appetite, gut motility, glucose control, or lipid levels within 4 weeks of enrolment.\n* Taking any dietary supplements, apart from vitamin D or calcium supplements, 4 weeks prior to enrolment.\n* Allergy or intolerance to any study food ingredients.\n* Unable\u002Fdislike\u002Funwilling to consume study foods or adhere to study protocol (e.g., not willing to drink a maximum 9 units of alcohol a week or consume animal products).\n* Currently reported pregnant or lactating.\n* Unwilling or unable to consume non-halal or non-kosher products.\n* Estimated energy requirements of \\\u003C1,500 kcal\u002Fday or \\>3,000 kcal\u002Fday.\n* Unexplained or unintentional weight loss in the past six months.","30 Years","70 Years",{"count":131,"type":22},248,[52],"The aim of this randomised controlled trial is to investigate the effects of plant foods on gastrointestinal and cardiometabolic health in healthy adults aged 30-70 years old. The main question it will answer is \"what is the effect of plant foods on alpha-diversity of the gut microbiota?\".\n\nResearchers will compare two diets containing plant foods to see if they have different effects on gastrointestinal and cardiometabolic health.\n\nParticipants will be asked to replace all their meals, snacks and drinks with those provided by the study team for four weeks (6 days\u002Fweek). Participants will also be asked to attend the research facility on three occasions to:\n\n* Provide a blood sample\n* Provide a urine sample\n* Provide a stool sample\n* Have their body composition assessed\n* Have an ultrasound of their artery (arm)\n* Have their blood pressure measured\n* Answer questionnaires related to dietary intake, mental health, physical activity, quality of life, diet acceptability and adherence",[28,135],"Nutrition","2026-05-07",{"date":138,"type":33},"2026-05-14",{"date":140,"type":22},"2026-04",{"date":142,"type":22},"2028-11",{"name":144,"class":67},"King's College London",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":16,"sex":17,"minAge":75,"maxAge":76,"enrollmentInfo":152,"targetDuration":4,"studyType":23,"phases":154,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":41},"100622364","phase-1-drug-drug-interaction-between-dw4421-and-amoxicillinclarithromycin-100622364","NCT07382661","Drug-Drug Interaction Between DW4421 and Amoxicillin\u002FClarithromycin","A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetics Drug-drug Interaction of DW4421 and Amoxicillin\u002FClarithromycin in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Inclusion Criteria:\n* Healthy adult aged 19 to 50 (inclusive) years, at the time of screening.\n* Subjects weighing between 50 kg and 90 kg with BMI between 18 and 27 kg\u002Fm2 (inclusive) at screening visit.\n\nExclusion Criteria:\n\n* Those who have clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history.",{"count":153,"type":22},36,[25],"Drug-Drug Interaction between DW4421 and Amoxicillin\u002FClarithromycin",[28],"2026-02-02",{"date":159,"type":33},"2026-02-04",{"date":161,"type":22},"2026-02",{"date":163,"type":22},"2026-10",{"name":90,"class":40}]